Table 3.
Representative incremental cost-effectiveness ratio for each drug indication in increasing order
| Drug | Indications | ICER ( in US$) * |
|---|---|---|
| Nilotinib | Chronic myeloid leukemia, chronic phase: 1st-line | 17,314 |
| Imatinib | Gastrointestinal stromal tumor: Adjuvant therapy | 29,591 |
| Cetuximab | Colorectal cancer (K-RAS wild type): 1st line with oxaliplatin, fluorouracil, and folinic acid | 42,026 |
| Pemetrexed | NSCLC (for non-squamous histology): 1st line with cisplatin | 44,451 |
| Lenalidomide | Multiple myeloma: 1st-line | 68,941 |
| Pemetrexed | NSCLC: Maintenance treatment | 73,978 |
| Sorafenib | Liver cancer: 1st line | 82,792 |
| Sunitinib | Renal cell carcinoma: 1st line | 85,572 |
| Lapatinib | Breast cancer with HER2 overexpression: 2nd line with capecitabine | 93,496 |
| Bevacizumab | Colorectal cancer: with irinotecan, fluorouracil, and leucovorin | 98,937 |
| Bevacizumab | Colorectal cancer: with oxaliplatin, fluorouracil, and folinic acid | 110,967 |
| Dasatinib | Chronic myeloid leukemia, chronic phase: 1st-line | 118,050 |
| Cetuximab | Colorectal cancer: with irinotecan | 121,528 |
| Temsirolimus | Renal cell carcinoma: 1st-line for poor prognosis patients | 128,595 |
| Bevacizumab | Renal cell carcinoma: 1st line with interferon-α | 131,070 |
| Crizotinib | NSCLC (ALK fusion positive): 2nd line (vs. docetaxel) | 158,133 |
| Bevacizumab | NSCLC: 1st line with platinum-based chemotherapy | 196,000† |
| Cetuximab | Head and neck cancer (squamous cell carcinoma) : 1st line with platinum-based chemotherapy | 261,767 |
| Erlotinib | Pancreatic cancer: 1st line with gemcitabine | 430,000‡ |
ICER, Incremental Cost Effectiveness Ratio; NSCLC, non-small cell lung cancer.
*Most ICER values except two indications were retrieved from the National Institute for Health and Clinical Excellence in United Kingdom (costs are expressed in US dollars; £1 equals $1.574 (as of January 29, 2013)).
†This value was from the Pharmaceutical Benefits Advisory Committee in Australia. (Canadian $1 equals US $0.98) http://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/psd/2011-03/pbac-psd-bevacizumab-march11.
‡This value was from Miksad RA et al. J Clin Oncol 25:4506–7; author reply 4508, 2007.